AbbVie Inc. (NYSE: ABBV) reported fourth quarter 2020 earnings results today. Worldwide net revenues rose 59.2% year-over-year to $13.8 billion on a
AbbVie (ABBV) Earnings: 4Q20 Key Numbers
Categories
pharmaceuticals
Pfizer (PFE) Q4 Earnings: Key financials and quarterly highlights
Pfizer Inc. (NYSE: PFE) reported its fourth quarter 2020 earnings results today. Revenues increased 12% year-over-year to $11.7 billion. On a GAAP
Infographic: Vertex Pharmaceuticals (VRTX) 4Q20 Earnings Results
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported fourth quarter 2020 earnings results today. Total revenues increased 15% year-over-year to $1.62 billion. GAAP net
Where do these companies stand in the COVID-19 vaccine race?
After the struggle with the COVID-19 pandemic and its impacts clouding most of 2020, the rollout of vaccines against COVID-19 is the
Johnson & Johnson’s (JNJ) single-dose vaccine is effective but lags behind rivals
Johnson & Johnson (NYSE: JNJ) is the latest pharma company to provide results from the trial of its COVID-19 vaccine candidate. The company
Fate Therapeutics (FATE) looks headed for a turnaround post-COVID
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market's attention after reporting positive results from advanced-stage clinical
Johnson & Johnson (JNJ): Strength in ecommerce drives growth in Consumer Health
Shares of Johnson & Johnson (NYSE: JNJ) gained nearly 3% in morning trade on Tuesday after the company reported fourth quarter 2020
Johnson & Johnson (JNJ) beats market estimates in Q4
Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2020 financial results before the regular market hours on Tuesday. The pharmaceutical giant reported fourth-quarter
Merck (MRK) pulls out of the COVID-19 vaccine race; will focus on investigational therapeutic candidates
Merck & Co. Inc. (NYSE: MRK) has decided to discontinue the development of its COVID-19 vaccine candidates after its clinical trials yielded
COVID-related medical costs may weigh on UnitedHealth’s performance this year
The health insurance sector has been facing multiple challenges from the virus crisis, but market-leading healthcare firm UnitedHealth Group (NYSE: UNH) maintained
Latest study shows Eli Lilly’s (LLY) antibody reduces COVID-19 by 80%
Eli Lilly and Company (NYSE: LLY) announced that the results from its latest study indicated that its monoclonal antibody bamlanivimab reduced the
Codexis (CDXS) may be moving closer to profitability, after beating slowdown
Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its partners to
Covid vaccine won’t dent Ampio Pharma’s market: CEO Michael Macaluso
Since its foundation in 2008, Ampio Pharmaceuticals (NYSE: AMPE) has been focused on delivering a drug that treats inflammation caused by a
Johnson & Johnson’s (JNJ) COVID-19 vaccine would have an edge over others without this glitch
Johnson & Johnson (NYSE: JNJ) saw its shares climb 2% on Thursday after the company reported positive results from the early-stage trials
Rite Aid (RAD) looks to regain lost ground with new rebound strategy
Rite Aid Corporation (NYSE: RAD) is on a mission to put the house in order and achieve sustainable profitability, after prolonged volatility
Trxade Group Inc. (NASDAQ: MEDS) Q4 2020 Research Summary
Ticker MEDSExchange NASDAQFounded 2013Headquarters FloridaIndustry TechnologyMarket Cap $45 million Trxade Group Inc (NASDAQ: MEDS) has been serving pharmacies and drug manufacturers for
COVID vaccine: Single-dose regimen can give Johnson & Johnson (JNJ) an edge
Johnson & Johnson (NYSE: JNJ) has adopted a slow and steady approach in its COVID vaccine research, which is one of the
Rite Aid Corporation (RAD) Q3 2021 Earnings Call Transcript
Rite Aid Corporation (NYSE: RAD) Q3 2021 earnings call dated Dec. 17, 2020. Corporate Participants: Trent Kruse -- Senior Vice President, Investor Relations and
Infographic: Highlights of Rite Aid’s (RAD) Q3 2021 earnings report
Rite Aid Corporation (NYSE: RAD) reported a decline in third-quarter earnings, despite an increase in revenues, as margins were hurt by higher
Alexion’s long-term prospects remain intact amid continued focus on rare diseases
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has stood out in the crowded pharmaceuticals marketplace by developing effective treatments for certain rare health conditions. The
Is it the right time to invest in Agilent Technologies (A)?
Agilent Technologies, Inc. (NYSE: A) ended fiscal 2020 on a positive note, bettering its performance consistently after experiencing a slowdown in the